[1]Kim S Y, Yasuda S, Tanaka H, et al. Non-clustered protocadherin [J].Cell Adh Migr,2011,5(2):97 [2]Hirano S. Pioneers in the ventral telencephalon: The role of OL-protocadherin-dependent striatal axon growth in neural circuit formation[J].Cell Adh Migr,2009,1(4):176 [3]Morrow E M, Yoo S Y, Flavell S W, et al. Identifying autism loci and genes by tracing recent shared ancestry[J]. Science, 2008, 321 (5886):218 [4]Redies C, Hertel N, Huebner C A. Cadherins and neuropsychiatric disorders[J].Brain Res,2012,1470:130 [5]Ying J, Li H, Seng T J, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation[J].Oncogene,2006,25(7):1070 [6]Yu B, Yang H, Zhang C, et al. High-resolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers[J].Neoplasma,2010,57(3):247 [7]Li Z, Chim J C, Yang M, et al. Role of PCDH10 and its hypermethylation in human gastric Cancer[J].Biochim Biophys Acta,2012,1823(2):298 [8]Heitzer E, Artl M, Filipits M, et al. Differential survival trends of stage II colorectal Cancer patients Relate to promoter methylation status of PCDH10, SPARC, and UCHL1[J].Mod Pathol,2014,27(6):906 [9]Ying J M, Gao Z F, Li H Y, et al. Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies[J].Br J Haematol,2007,136(6):829 [10]Harada H, Miyamoto K, Yamashita Y, et al. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer[J].Cancer Med,2015,4(10):1536 [11]Narayan G, Xie D, Freddy A J, et al. PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis[J].Genes Chromosomes Cancer,2013,52(11):1030 [12]Lin Y L, Li Z G, He Z K, et al. Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer[J].J Int Med Res,2012,40(6):2117 [13]Li Z S, Li W J, Xie J, et al. Epigenetic inactivation of PCDH10 in human prostate cancer cell lines[J].Cell Biol Int,2011,35(7):671 [14]Yu J, Cheng Y Y, Tao Q, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer[J].Gastroenterology,2009,136(2):640 [15]Hou Y C, Deng J Y, Zhang R P, et al. Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer[J].Cancer Biomark,2015,15(5):567 [16]Jao T M, Tsai M H, Lio H Y, et al. Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal Cancer and its genetic loss predicts adverse prognosis[J].Int J Cancer,2014,135(11):2593 [17]Ma J G, He Z K, Ma J H, et al. Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer[J].J Int Med Res,2013,41(1):38 [18]Fang S, Huang S F, Cao J, et al. Silencing of PCDH10 in hepatocellular carcinoma via de novo DNA methylation Independent of HBV infection or HBX expression[J].Clin Exp Med,2013,13(2):127 [19]Narayan G, Scotto L, Neelakantan V, et al. Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer[J].Genes Chromosomes Cancer,2009,48(11):983 [20]Zhao Y, Yang Y, Trovik J, et al. A novel wnt regulatory axis in endometrioid endometrial cancer[J].Cancer Res,2014,74(18):5103 [21]Li Y, Yang Z S, Song J J, et al. Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma[J].Int J Mol Med,2012,29(4):704 [22]Zhong X, Zhu Y, Mao J, et al. Frequent epigenetic silencing of PCDH10 by methylation in human colorectal cancer[J].J Cancer Res Clin Oncol,2013,139(3):485 [23]Tang X K, Yin X E, Xiang T X, et al. Protocadherin 10 is frequently downregulated by promoter methylation and functions as a tumor suppressor gene in non-small cell lung Cancer[J].Cancer Biomark, 2012,12(1):11 [24]Li Z, Yang Z, Peng X, et al. Nuclear factor-κB is involved in the protocadherin-10-mediated pro-apoptotic effect in multiple myeloma [J].Mol Med Rep,2014,10(2):832 [25]Deng J, Liang H, Ying G, et al. Clinical significance of the methylated cytosine-phosphate-guanine sites of protocadherin-10 promoter for evaluating the prognosis of gastric cancer[J].J Am Coll Surg, 2014,219(5):904 [26]Schneider B G, Mera R, Piazuelo M B, et al. DNA methylation predicts progression of human gastric lesions[J].Cancer Epidemiol Biomarkers Prev,2015,24(10):1607 [27]Wang L, Xie P G, Lin Y L, et al. Aberrant methylation of PCDH10 predicts worse biochemical recurrence-free survival in patients with prostate cancer after radical prostatectomy[J].Med Sci Monit,2014,20:1363 [28]Lin C J, Lai H C, Wang K H, et al. Testing for methylated PCDH10 or WT1 is superior to the HPV test in detecting severe neoplasms (CIN3 or greater) in the triage of ASC-US smear results[J].Am J Obstet Gynecol,2011,204(1):21 [29]Danese E, Minicozzi A M, Benati M, et al. Epigenetic alteration: new insights moving from tissue to plasma - the example of PCDH10 promoter methylation in colorectal cancer[J].Br J Cancer,2013,109(3):807 [30]Narayan G, Freddy A J, Xie D X, et al. Promoter Methylation-Mediated inactivation of PCDH10 in acute lymphoblastic leukemia contributes to chemotherapy resistance[J].Genes Chromosomes Cancer, 2011, 50 (12): 1043
[1]陈赛鹏,王嘉南,王 林,等.基于TCGA数据库分析甲基化促进精原细胞瘤进程的作用机制[J].天津医科大学学报,2019,25(05):463.
CHEN Sai-peng,WANG Jia-nan,WANG Lin,et al.Integrated analysis of the mechanism of methylation promoting the progress of seminomas based on the TCGA database[J].Journal of Tianjin Medical University,2019,25(02):463.
[2]张静怡,迟航,杨鑫,等.Ras相关区域家族10蛋白在非小细胞肺癌中的表达及预后价值[J].天津医科大学学报,2024,30(05):385.[doi:10.20135/j.issn.1006-8147.2024.05.0385]
ZHANG Jingyi,CHI Hang,YANG Xin,et al.The expression and prognostic value of ras-association domain family 10 in non-small cell lung cancer[J].Journal of Tianjin Medical University,2024,30(02):385.[doi:10.20135/j.issn.1006-8147.2024.05.0385]